



# UKMF Spring Day

## Personalised Therapy in Myeloma: Fact or Fiction?

### Wednesday 22<sup>nd</sup> March 2017

Brunei Gallery, School of Oriental and African Studies, Thornhaugh Street, London WC1H 0XG

09.30	<i>Registration</i>		<b>Chair: Professor Graham Jackson</b>
10.00	Making sense of prognostic factors		<b>Dr Dean Smith</b> <i>University College London</i>
	<b>Biomarkers for Personalised Therapy in Myeloma</b>		
10.25	Actionable/driver mutations in myeloma		<b>Dr Mike Chapman</b> <i>University of Cambridge</i>
10.45	Hevylite assays de-convoluted		<b>Dr Karthik Ramasamy</b> <i>Oxford University Hospitals</i>
11.00	MRD testing: which platforms, which patients?		<b>Dr Roger Owen</b> <i>St James's Institute of Oncology, Leeds</i>
11.20	Biomarkers for frailty		<b>Professor Gordon Cook</b> <i>St James's Institute of Oncology, Leeds</i>
11.40	<b>Keynote Lecture:</b> The patient's perspective		<b>Mr Eric Low</b> <i>Former Chief Executive of Myeloma UK</i>
12.10	<i>Lunch</i>		
		<b>Chair: Dr Neil Rabin</b>	
13.00	<b>Michael Morley Lecture:</b> Understanding the myeloma environment		<b>Professor Irene Ghobrial</b> <i>Harvard Medical School, Boston, USA</i>
	<b>ASH Bursary Winners</b>		
14.00	An APRIL based chimeric antigen receptor to simultaneously target BCMA and TACI in multiple myeloma has potent activity in vitro and in vivo		<b>Dr Lydia Lee</b> <i>UCL Cancer Institute</i>
14.15	Transcriptome profiling of the myeloma-bone niche identifies BMP signalling as a therapeutic target for bone maintenance		<b>Dr Sarah Gooding</b> <i>University of Oxford</i>
14.30	<i>Coffee</i>		
15.00	<b>Tributes to Eric Low</b>		<b>Led by: Professor Steve Schey and Professor Kwee Yong</b>
16.15	<i>Summary and close</i>		

**Registration Fee: £60 (£40 for Scientists and Nurses)**

**For online registration please visit [www.hartleytaylor.co.uk](http://www.hartleytaylor.co.uk)**

For further information please email [ukmf@hartleytaylor.co.uk](mailto:ukmf@hartleytaylor.co.uk) or telephone 01296 584172 / 07900 634948

*The following companies have supported the meeting by purchasing exhibition stand space and delegate places but have had no input into the programme, selection of speakers or topics:*

